Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Ph...